The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.
At NephCure, our mission is fueled by the passion and commitment of our diverse team, united in the fight against rare, protein-spilling kidney diseases. Get to know the faces behind the mission.
Explore career opportunities at NephCure, where passion meets purpose. Our dedicated team is committed to advancing research, supporting patients, and raising awareness for rare kidney diseases. Explore rewarding career opportunities today.
JOIN THE TEAM